Status:
RECRUITING
A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-99 years
Brief Summary
This is a prospective, multicenter, observational, non-interventional study (NIS) in patients with Multiple Sclerosis (MS) and routinely assessed serum neurofilament light (sNfL) values in Germany
Detailed Description
Prospective, primary data will be collected from patients with sNfL outcomes in the context of switching to ofatumumab or continuing their current therapy. Data collection will cover a maximum period ...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
October 28 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 29 2028
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT06551519
Start Date
October 28 2024
End Date
November 29 2028
Last Update
March 9 2026
Active Locations (108)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Albstadt, Baden-Wurttemberg, Germany, 72458
2
Novartis Investigative Site
Hettingen, Baden-Wurttemberg, Germany, 72513
3
Novartis Investigative Site
Mannheim, Baden-Wurttemberg, Germany, 68163
4
Novartis Investigative Site
Schwetzingen, Baden-Wurttemberg, Germany, 68723